Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1 Completed 30 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus in treating patients with metastatic or unresectable solid tumors.

Timeline

Start: 2004-12
Primary completion: 2009-06
Completion: 2009-06

Publications

Results Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 1;26(25):4172-9. doi: 10.1200/JCO.2008.16.2347.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	2 mg	Oral
Subject	Sirolimus	Small molecule	3 mg	Oral
Subject	Sirolimus	Small molecule	6 mg	Oral
Subject	Sirolimus	Small molecule	9 mg	Oral

Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors

Summary

Timeline

Publications

Drugs

Indications